Publications by authors named "Binlin Ma"

19 Publications

  • Page 1 of 1

Rapid identification of papillary thyroid carcinoma and papillary microcarcinoma based on serum Raman spectroscopy combined with machine learning models.

Photodiagnosis Photodyn Ther 2021 Nov 21:102647. Epub 2021 Nov 21.

College of Software, Xinjiang University, Urumqi, 830046, China.; Key Laboratory of Signal Detection and Processing, Xinjiang University, Urumqi, 830046, China.; College of Information Science and Engineering, Xinjiang University, Urumqi, 830046, China.

Thyroid carcinoma is one kind of cancer with the highest diagnosis rate in the endocrine system, and its main histological subtype is papillary thyroid carcinoma (PTC) accounting for 80% of thyroid malignancies. In recent years, the incidence of thyroid cancer has increased exponentially, and its substantial increase was closely related to the overdiagnosis of papillary microcarcinoma (PMC). Therefore, early and accurate identification of PTC and PMC can prevent patients from being irreversibly damaged. This study aimed to identify PTC and PMC using Raman spectroscopy. We collected serum Raman spectra from 16 patients with PTC and 31 patients with PMC. Firstly, the collected imbalance data were preprocessed using the synthetic minority over-sampling technique (SMOTE). Then, the equalized data were dimensionality reduced by principal component analysis (PCA). Finally, the processed data were fed into the single decision tree (DT) classifier, as well as the random forest (RF) built on the idea of Boosting ensemble and the Adaptive Boosting (Adaboost) model built on the idea of Bagging ensemble for classification. The classification accuracy of the three models in the testing set were 75.38%, 81.54%, and 84.61%, respectively. Compared with the DT classifier, the accuracy of the models introducing the idea of ensemble learning was enhanced by 6.16% and 9.23%, respectively. The best model was the Adaboost. This result demonstrates that serum Raman spectroscopy combined with an ensemble learning algorithm was feasible in rapidly identifying PTC and PMC. At the same time, the method has great potential for application in the field of clinical diagnosis.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pdpdt.2021.102647DOI Listing
November 2021

The durability of flexible eddy current array (FECA) sensors in harsh service environments.

Sci Rep 2021 May 14;11(1):10341. Epub 2021 May 14.

Aeronautic Engineering College, Air Force Engineering University, 1 Baling Road, Xi'an, 710038, China.

Sensors for structural health monitoring (SHM) need to be permanently integrated on structures and withstand the harsh service environments, which has been a big challenge for the application of SHM in aircrafts. This paper focuses on the durability of flexible eddy current array (FECA) sensors in harsh service environments of aircrafts, including vibration environment and several typical exposed environments. First, a kind of FECA sensor is illustrated and its integration method is proposed. Moreover, in order to study the durability of the sensor in vibration environment, the modal analysis is performed by the finite element method. According to the simulation results, the durability experiment in vibration environment is carried out under the fourth order vibration mode, which makes the sensor suffer the harshest vibration loads. During the vibration experiment, output signals of the sensor keep stable and the sensor is well bonded to the structure, which shows the integrated sensor has high durability in vibration environment. Finally, the durability of integrated sensors is separately tested in three exposed environments, including salt fog corrosion environment, fluid immersion environment, as well as hygrothermal and ultraviolet-radiation environment. After these environmental exposure experiments, all sensors are well bonded to structures and can effectively monitor fatigue cracks, which shows great durability. Therefore, FECA sensors can survive in harsh service environments of aircrafts, which provides important support for the engineering applications of FECA sensors.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-021-89750-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8121915PMC
May 2021

Targeting a novel LncRNA SNHG15/miR-451/c-Myc signaling cascade is effective to hamper the pathogenesis of breast cancer (BC) in vitro and in vivo.

Cancer Cell Int 2021 Mar 31;21(1):186. Epub 2021 Mar 31.

Department of Breast and Thyroid Surgery, The 3rd Affiliated Teaching Hospital of Xinjiang Medical University (Affiliated Cancer Hospital), Suzhou East Street No. 789, Xinshi District, Urumqi, 830011, Xinjiang, China.

Background: To our knowledge, LncRNA SNHG15 exerted its tumor-promoting effects to facilitate the development of breast cancer (BC), but there still needed more data to elucidate the potential underlying mechanisms.

Methods: We examined genes expression status by performing Real-Time qPCR and Western Blot analysis, and cellular functions, including cell proliferation, viability, apoptosis, mobility, were measured by using the CCK-8 assay, colony formation assay, trypan blue staining assay, flow cytometer (FCM), transwell assay and wound scratch assay, respectively. The predicted targeting sites in LncRNA SNHG15, miR-451 and c-Myc 3'UTR were validated by dual-luciferase reporter gene system assay. Finally, we established the tumor-bearing mice models, and the expression status, including its enrichment and cellular localization were examined by immunohistochemistry (IHC) assay.

Results: Our data indicated LncRNA SNHG15 upregulated c-Myc to facilitate BC progression by sponging miR-451 in a competing endogenous RNA (ceRNA)-dependent manner in vitro and in vivo. Specifically, LncRNA SNHG15 and c-Myc were upregulated, while miR-451 was downregulated in BC cells and clinical tissues, compared to their normal counterparts. In addition, miR-451 negatively correlated with LncRNA SNHG15 and c-Myc, and LncRNA SNHG15 was positively relevant to c-Myc in BC tissues. Next, we validated that LncRNA SNHG15 sponged miR-451 to upregulate c-Myc in BC cells. Further gain- and loss-of-function experiments evidenced that LncRNA SNHG15 promoted, while miR-451 inhibited malignant phenotypes, including cell proliferation, viability, migration, invasion and epithelial-mesenchymal transition (EMT) in BC cells. Interestingly, the inhibiting effects of LncRNA SNHG15 ablation on BC progression were abrogated by both silencing miR-451 and overexpressing c-Myc.

Conclusions: We concluded that targeting the LncRNA SNHG15/miR-451/c-Myc signaling cascade was novel to hamper BC progression, which broadened our knowledge in this field, and provided potential biomarkers for BC diagnosis and treatment.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12935-021-01885-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8097789PMC
March 2021

BRCA1 subcellular localization regulated by PI3K signaling pathway in triple-negative breast cancer MDA-MB-231 cells and hormone-sensitive T47D cells.

Open Life Sci 2020 10;15(1):501-510. Epub 2020 Jul 10.

Department of Breast and Head & Neck, The Affiliated Cancer Hospital of Xinjiang Medical University, No. 789 Suzhou East Street, Urumqi 830011, Xinjiang, P. R. China.

This study is to investigate the effect of the PI3K/Akt signaling pathway on the regulation of BRCA1 subcellular localization in triple-negative breast cancer (TNBC) MDA-MB-231 cells and hormone-sensitive T47D cells. We found that heregulin-activated T47D cells showed more nuclear localization of BRCA1, but BRCA1 nuclear localization decreased after the inhibition of the PI3K signaling pathway. In MDA-MB-231 cells, activation or inhibition of the PI3K signaling pathway did not significantly affect cell apoptosis and BRCA1 nuclear translocation ( > 0.05). However, in T47D cells, the activation of the PI3K pathway significantly increased cell apoptosis ( < 0.05). In the heregulin-activated MDA-MB-231 and T47D cells, the phosphorylation of Akt and BRCA1 was significantly increased ( < 0.05), while that was significantly reduced after PI3K pathway inhibition ( < 0.05). The changing trends of the mRNA levels of and in MDA-MB-231 and T47D cells after PI3K pathway activation or inhibition were consistent with the trends of their proteins. In both MDA-MB-231 and T47D cells, BRCA1 phosphorylation is regulated by the PI3K signaling pathway, but the nuclear localization of BRCA1 is different in these two cell lines. Moreover, the apoptosis rates of these two cell lines are different.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1515/biol-2020-0054DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7874579PMC
July 2020

Expression and prognosis analysis of GINS subunits in human breast cancer.

Medicine (Baltimore) 2021 Mar;100(11):e24827

Department of Breast, Head and Neck Surgery.

Abstract: GINS subunits, a protein complex composed of GINS1, GINS2, GINS3 and GINS4 in the human genome and the expression level of each GINS subunits plays an important role in different human cancers. As one of the most common malignancies after lung cancer in the world, precise biomarkers for early diagnosis and treatment in breast cancer are important. The purpose of our study was to elucidate the expression and prognostic value of GINS subunits in breast cancer.The purpose of present study was to explore the expression level of GINS subunits in breast cancer patients.In the present study, we investigated the gene alteration, gene expression and potential prognostic value of GINS subunits by using the Gene Expression Profiling Interactive Analysis (GEPIA), UALCAN, cBioPortal, and bc-GenExMiner databases. Then, the GeneMANIA database was used to show the genes that associated with GINS subunits. Furthermore, gene ontology pathway analysis was conducted by using the Metascape database. Finally, immune infiltration analysis in GINS subunits were evaluated using the Tumor Immune Estimation Resource (TIMER) database.Our analyses demonstrated that the expression levels of different GINS subunits were different between breast cancer and normal breast tissues. The expression levels of GINS1, GINS2, and GINS4 were significantly higher in breast cancer tissues than in normal tissues. Survival analysis revealed that increased the expression levels of GINS subunits were associated with poor prognoses in all patients with breast cancer. Gene ontology pathway enrichment analysis of the GINS subunits suggested that GINS subunits involved in pathways including the cell cycle checkpoint, DNA replication and other meaningful signaling pathways.We systemically analyzed the expression, prognostic, clinicopathologic values, and potential functional networks of GINS subunits in breast cancer. Our findings showed that individual GINS subunits could be new potential prognostic biomarkers for breast cancer. However, further verification studies are still needed to prove the clinical value of GINS subunits in breast cancer patients.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000024827DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982226PMC
March 2021

UBE2T promotes proliferation, invasion and glycolysis of breast cancer cells by regualting the PI3K/AKT signaling pathway.

J Recept Signal Transduct Res 2021 Jan 12:1-9. Epub 2021 Jan 12.

Department of Breast, Head and Neck Surgery, Xinjiang Medical University affiliated Tumor Hospital, Urumqi, China.

Purpose: Breast cancer (BCa) is one of the most common gynecological malignancies. Ubiquitin-coupled enzyme E2T (UBE2T) has been demonstrated to play crucial roles in various tumors.

Methods: UBE2T levels were detected using quantitative real time PCR and western blot. CCK-8 and colony formation assays were used to evaluate cell proliferation. A xenograft model was used to evaluate the effects of UBE2T on tumor growth in mice, and immunohistochemistry (IHC) assay was performed to detect the expression of UBE2T and Ki-67. Transwell assay was performed to determine cell migration and invasion. The ATP level, glucose consumption and lactate production were measured using the corresponding commercial kits. Western blot assay was used to detect the levels of epithelial-mesenchymal transformation (EMT), glycolytic and the PI3K/AKT pathway related proteins regulated by UBE2T.

Results: Upregulation of UBE2T expression in human BCa tissues was found in human clinical BCa tissues and The Cancer Genome Atlas (TCGA) dataset. The expression of UBE2T was confirmed to be up-regulated in BCa cells compared to normal breast epithelial cell line (MCF-10A). Overexpression of UBE2T promoted proliferation, migration, invasion and glycolysis in BCa cells, while UBE2T knockdown showed the opposite results. Moreover, UBE2T knockdown suppressed tumor growth in mice. Further mechanism analysis shows that UBE2T participated in the regulation of BCa progression through affecting the PI3K/AKT signaling pathway.

Conclusion: UBE2T promoted proliferation, invasion and glycolysis through modulating PI3K/AKT signaling pathway in BCa, implying that UBE2T may provide a promising therapeutic target for the therapy of BCa.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1080/10799893.2020.1870495DOI Listing
January 2021

Correlation between ZBRK1/ZNF350 gene polymorphism and breast cancer.

BMC Med Genomics 2021 01 6;14(1). Epub 2021 Jan 6.

Surgical Department of Breast, Head and Neck Surgery, The Third Clinical Medical College of Xinjiang Medical University (The Affiliated Tumor Hospital), No. 789, Suzhou East Street, Urumqi, 830011, Xinjiang, China.

Background: This study is to explore the relationship between the ZBRK1/ZNF350 (Zinc finger and BRCA1-interacting protein with KRAB domain-1; also known as zinc-finger protein 350) gene polymorphism and early-onset breast cancer.

Methods: The ZBRK1/ZNF350 gene exon detection analysis was performed with the direct sequencing and Snapshot methods in 80 cases of breast cancer (aged ≤ 40 years old) and 240 healthy subjects (aged ≤ 40 years old).

Results: Totally 9 sequence variants were detected, including 5 missense mutations and 4 synonymous mutations, located at EXON3, EXON4 and EXON5, respectively. The rs4987241 and rs3764538 variants were published for the first time, while the remaining variants had been reported before. There were significant differences in the frequency distribution of family history between the breast cancer and control groups. Moreover, there were significant differences in the CT genotype frequency at the rs138898320 locus between the breast cancer and healthy control groups. Compared with the carriers of CC wild genotype at rs138898320, the risk of breast cancer was reduced by 88.3% in the CT mutant genotype carriers, with significant difference. In the stratification with no family history, compared with the carriers of CC wild genotype at rs138898320, significant differences were observed for the CT mutant genotype carriers. In the stratification with family history, there was no significant difference in the variation of rs138898320.

Conclusion: The rs138898320 CT mutation genotype of ZBRK1/ZNF350 may reduce the risk of breast cancer, and the protecting effect would be increased in the stratification with no family history. Trial registration Not applicable.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12920-020-00862-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7788962PMC
January 2021

Oncolytic herpes simplex virus and temozolomide synergistically inhibit breast cancer cell tumorigenesis and .

Oncol Lett 2021 Feb 8;21(2):99. Epub 2020 Dec 8.

Breast Cancer Center, Department of Breast and Thyroid Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510630, P.R. China.

The oncolytic herpes simplex virus (HSV) G47Δ can selectively eliminate glioblastoma cells via viral replication and temozolomide (TMZ) has been clinically used to treat glioblastoma. However, the combined effect of G47Δ and TMZ on cancer cells, particularly on breast cancer cells, remains largely unknown. The objective of the present study was to investigate the role and underlying mechanism of G47Δ and TMZ, in combination, in breast cancer cell tumorigenesis. The human breast cancer cell lines SK-BR-3 and MDA-MB-468 were treated with G47Δ and TMZ individually or in combination. Cell viability, flow cytometry, reverse transcription quantitative-PCR and western blotting were performed to investigate the synergy between G47Δ and TMZ in regulating breast cancer cell behavior . The role of G47Δ and TMZ in suppressing tumorigenesis was investigated in a xenograft mouse model. G47Δ and TMZ served a synergistic role resulting in decreased breast cancer cell viability, induction of cell cycle arrest, promotion of tumor cell apoptosis and enhancement of DNA damage response . The combined administration of G47Δ and TMZ also effectively suppressed breast cancer cell-derived tumor growth , compared with the administration of G47Δ or TMZ alone. Synergy between G47Δ and TMZ was at least partially mediated via TMZ-induced acceleration of G47Δ replication, and such a synergy in breast cancer cells and provides novel insight into the future development of a therapeutic strategy against breast cancer.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.3892/ol.2020.12360DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751368PMC
February 2021

Distribution and susceptibility of ERCC1/XPF gene polymorphisms in Han and Uygur women with breast cancer in Xinjiang, China.

Cancer Med 2020 12 16;9(24):9571-9580. Epub 2020 Oct 16.

Department of Breast Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.

This study aimed to explore the roles of ERCC1/XPF gene polymorphisms in the occurrence of breast cancer in the Uygur and Han ethnic groups in Xinjiang, China. Single nucleotide polymorphisms (SNPs) were detected by TaqMan real-time PCR. The rs11615 G>A and rs2276466 C>G variant frequencies were higher in Uygur patients with breast cancer than in Han patients, while the frequency of rs2298881 C>A was higher in Han patients. We found that rs2298881 C>A (CA vs. CC: OR = 0.35, 95% CI = 0.20-0.60; AA vs. CC: OR = 0.13, 95% CI = 0.04-0.34; CA + AA vs. CC: OR = 0.33, 95% CI = 0.18-0.51; AA vs. CA + CC: OR = 0.24, 95% CI = 0.08-0.62; CA vs. AA + CC: OR = 0.49, 95% CI = 0.29-0.82) was associated with a reduced breast cancer risk and rs3212986 C>A (AA vs. CC: OR = 4.80, 95% CI = 1.79-15.29,; CA+AA vs. CC: OR = 1.71, 95% CI = 1.06-2.77; AA vs. CA+CC: OR = 4.12, 95% CI =1.58-12.89) and rs11615 G > A (AA vs. GG: OR = 3.49, 95% CI =1.54-8.55; GA + AA vs. GG: OR = 1.98, 95% CI = 1.21-3.27; AA vs. GA+GG: OR = 2.87, 95% CI = 1.30-6.85) were associated with an elevated breast cancer risk among Uygur individuals. In addition, Uygur patients with breast cancer with 2-3 combined risk genotypes of ERCC1 had a higher risk than patients with 0-1 risk genotypes (OR = 2.91; 95% CI = 1.54-5.71, p = 0.001). However, we failed to detect a statistically significant association between ERCC1/XPF polymorphisms and breast cancer risk in five genetic models among Han individuals. Our results showed that ERCC1/XPF gene polymorphisms predispose Uygur individuals to breast cancer; this finding should be verified by further large-scale analyses.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3547DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7774751PMC
December 2020

Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial.

J Clin Oncol 2020 06 10;38(16):1774-1784. Epub 2020 Apr 10.

Department of Breast Surgery, The Second Affiliated Hospital of Zhongshan University, Guangzhou, Guangdong, People's Republic of China.

Purpose: Standard adjuvant chemotherapy for triple-negative breast cancer (TNBC) includes a taxane and an anthracycline. Concomitant capecitabine may be beneficial, but robust data to support this are lacking. The efficacy and safety of the addition of capecitabine into the TNBC adjuvant treatment regimen was evaluated.

Patients And Methods: This randomized, open-label, phase III trial was conducted in China. Eligible female patients with early TNBC after definitive surgery were randomly assigned (1:1) to either capecitabine (3 cycles of capecitabine and docetaxel followed by 3 cycles of capecitabine, epirubicin, and cyclophosphamide) or control treatment (3 cycles of docetaxel followed by 3 cycles of fluorouracil, epirubicin, and cyclophosphamide). Randomization was centralized without stratification. The primary end point was disease-free survival (DFS).

Results: Between June 2012 and December 2013, 636 patients with TNBC were screened, and 585 were randomly assigned to treatment (control, 288; capecitabine, 297). Median follow-up was 67 months. The 5-year DFS rate was higher for capecitabine than for control treatment (86.3% 80.4%; hazard ratio, 0.66; 95% CI, 0.44 to 0.99; = .044). Five-year overall survival rates were numerically higher but not significantly improved (capecitabine, 93.3%; control, 90.7%). Overall, 39.1% of patients had capecitabine dose reductions, and 8.4% reported grade ≥ 3 hand-foot syndrome. The most common grade ≥ 3 hematologic toxicities were neutropenia (capecitabine, 136 [45.8%]; control, 118 [41.0%]) and febrile neutropenia (capecitabine, 50 [16.8%]; control, 46 [16.0%]). Safety data were similar to the known capecitabine safety profile and generally comparable between arms.

Conclusion: Capecitabine when added to 3 cycles of docetaxel followed by 3 cycles of a 3-drug anthracycline combination containing capecitabine instead of fluorouracil significantly improved DFS in TNBC without new safety concerns.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.19.02474DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255982PMC
June 2020

Chinese multicentre prospective registry of breast cancer patient-reported outcome-reconstruction and oncoplastic cohort (PRO-ROC): a study protocol.

BMJ Open 2019 12 15;9(12):e032945. Epub 2019 Dec 15.

Department of Breast Surgery, Shanghai Cancer Hospital, Fudan University, Shanghai, China

Introduction: Available patient-reported outcome (PRO) studies are mainly from single institution or of small sample size, and the variations across hospitals and regions were not fully analysed. A multicentre, prospective, patient-reported outcome-reconstruction and oncoplastic cohort (PRO-ROC) will be planned to assess the PROs of Chinese patients with breast cancer who will undergo breast reconstruction (BR) or oncoplastic breast-conserving surgery (OBCS).

Methods And Analysis: The inclusion criteria are female patients with breast cancer aged >18 years old who will undergo BR or OBCS. This cohort will include at least 10 000 consecutive patients (about 5000 patients who will undergo BR and 5000 patients who will undergo OBCS). The exposures were surgery types: BR and OBCS regardless of the techniques and materials used. The primary endpoint will be PROs, which include BREAST-Q and quality of life (European Organisation for Research and Treatment (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30) and EORTC QoL Breast Cancer-specific version (QLQ-BR23)). All patients will be followed up to 24 months after operations. All data will be prospectively collected using an app software. Data will be analysed using SPSS and Stata software.

Ethics And Dissemination: This study follows the Helsinki Declaration. All patients will be asked to sign an informed consent before enrolment. The results of this study will be presented at national and international meetings and published in a scientific peer-reviewed journal.

Trial Registration Number: NCT04030845; Pre-results.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1136/bmjopen-2019-032945DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6924782PMC
December 2019

PRKDC regulates chemosensitivity and is a potential prognostic and predictive marker of response to adjuvant chemotherapy in breast cancer patients.

Oncol Rep 2017 06 9;37(6):3536-3542. Epub 2017 May 9.

Department of Breast and Head & Neck, The Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830011, P.R. China

DNA-dependent kinase catalytic subunit (DNA-PKcs) is a critical component of DNA repair machinery and is found to be up- or down-regulated in different cancer types. However, its clinical significance in breast cancer remains unclear. To this end, quantitative PCR was performed to measure PRKDC expression level in 59 pairs of breast cancer tissues and the non-tumor adjacent tissues (NATs). The correlation between PRKDC expression and overall survival (OS) as well as the prognostic value of PRKDC were analyzed. In vitro and in vivo effects of PRKDC on chemosensitivity were evaluated in MCF-7 cells. We found that PRKDC expression was significantly increased in breast cancer tissue samples compared with NATs. High PRKDC expression was associated with higher tumor grade (P=0.001), positive lymph node metastasis (P=0.0357) and chemoresistance (P=0.0006). Furthermore, PRKDC expression was significantly correlated with OS in breast cancer patients with (0.0101) or without (P=0.0216) receiving chemotherapy. PRKDC was an independent prognostic factor of OS in breast cancer (P=0.022, hazard ratio=2.69, 95% confidence interval: 1.81-3.84). Moreover, downregulation of PRKDC sensitized MCF-7 cells to chemo-drugs both in vitro and in a xenografted mouse model. Collectively, our study demonstrated that PRKDC is a prognostic biomarker for chemoresistance in breast cancer patients.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.3892/or.2017.5634DOI Listing
June 2017

Comparison of Clinicopathological Features and Treatments between Young (≤40 Years) and Older (>40 Years) Female Breast Cancer Patients in West China: A Retrospective, Epidemiological, Multicenter, Case Only Study.

PLoS One 2016 31;11(3):e0152312. Epub 2016 Mar 31.

Department of Endocrine and Breast Surgery, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

The incidence of young cases of breast cancer is higher in China compared to the western world. We aimed to explore differences in risk factors, clinicopathological features and treatment modes of young female breast cancer compared to older patients in West China. We collected clinical information from 12,209 female breast cancer patients in West China, including risk factors, clinicopathological features and treatment modes, from January 2010 to December 2012. Chi-square tests and the multivariate logistic regression analysis were applied for statistical analysis. There were 2,682 young (≤40 years) cases and 9,527 older cases at the time of breast cancer diagnosis. Young patients had a greater tumor diameter at diagnosis, and a higher probability of axillary lymph node and distant metastasis (P < 0.05). The progesterone receptor positive expression rate, estrogen receptor/progesterone receptor double positive expression rate, and human epidermal growth factor receptor 2 (HER2) negative expression rate was higher in young patients compared to older patients (P < 0.05). For young patients, the age at menarche was earlier, they had lower marriage rates, fewer pregnancies and births, and a lower breastfeeding rate (P < 0.05). A higher proportion of young patients underwent advanced operations, neoadjuvant and adjuvant chemotherapy, radiotherapy, and endocrine therapy compared to older patients (P < 0.05). We found significant differences in the clinicopathological features, risk factors and treatment modes between young (≤40 years) and older (>40 years) female breast cancer patients in West China. As some of these results differ from those found in the western female population, it is likely that the mechanism of tumorigenesis of young female breast cancer patients in West China may differ from that in western developed countries. Further investigation into the regional differences in breast cancer tumorigenesis is warranted.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0152312PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4816508PMC
August 2016

Relationship between ultrasound elastography and myofibroblast distribution in breast cancer and its clinical significance.

Sci Rep 2016 Feb 5;6:19584. Epub 2016 Feb 5.

Department of Ultrasound, the Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi 830011, Xinjiang, China.

The study investigated the relationship between ultrasound elastography (USE) scoring and myofibroblast distribution with expression features of α-SMA +/CD34- in patients of Uyghur and Han ethnicities with breast masses in Xinjiang, China. The data was used to evaluate its clinical significance in the early diagnosis of breast cancer. A total of 300 patients with breast masses were included in the study, which involved conventional sonography and USE, with histopathologic diagnosis as the reference standard. Myofibroblast distribution was investigated by detecting the expression levels of α-SMA and CD34 in lesions using immunohistochemistry and real-time PCR. Out of 300 lesions, 185 were histologically malignant and 115 benign. The mean elasticity score for malignant lesions was significantly higher than for benign lesions. The expression level of α-SMA was elevated while the expression level of CD34 was lower in malignancies, compared with benign lesions. The expression of α-SMA was positively associated with the USE scores, while a negative relationship was observed between CD34 expression and USE scoring. The combination of USE and molecular diagnosis provides a promising modality for the early diagnosis and evaluation of the risks in particular types of breast cancer.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1038/srep19584DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4742804PMC
February 2016

A retrospective study of the clinical differences of Uygur breast cancer patients compared to Han breast cancer patients in the Xinjiang region of China.

Int J Clin Exp Med 2014 15;7(10):3482-90. Epub 2014 Oct 15.

Department of Breast and Neck, The Affiliated Tumor Hospital of Xinjiang Medical University 789 East Suzhou Street, Urumqi 830011, Xinjiang, China.

Background: Studies support biological disparities of breast cancer among races/ethnicities. Uygur is a minority ethnic group in China with a genetic admixture of Caucasian and East Asian. The Han ethnic group makes up the majority of the Chinese population. We aim to study and compare the clinical differences and survival rate in these two ethnic groups in order to improve prophylaxis.

Methods: A retrospective analysis of the medical records of 264 Uygur and 287 Han breast cancer patients including demographic data, clinical and pathological parameters, TNM status, Ki-67 and treatment information was collected. The patients were followed up at three month intervals for 2 years then every 6 months for 3 to 4 years postoperatively. Chi-square tests were performed to compare characteristics, and a log-rank test was used for ranked data. Overall survival and disease free survival were analyzed by Kaplan Meier tests.

Results: Uygur was statistically different in terms of: marital status; occupation; body mass index; duration of breast feeding; period of complaint; pathological composition; size of primary tumor; number of metastatic and resected lymph nodes; pathological staging; expression of nm23; chemotherapy and radiotherapy. The 5-year overall survival rate of Uygur breast cancer patients was 89.2% compared to 91.7% in Han (P = 0.129). The disease free survival of Uygur breast cancer patients was 79.3% compared to 84.5% in Han (P = 0.040).

Conclusion: The different characteristics of Uygur breast cancer patients compared to Han breast cancer patients and their lower survival rates indicate that management strategies should be implemented to improve patient outcome.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4238510PMC
November 2014

[The study of clinical long-term effect and prognostic factors in nasopharyngeal carcinoma after intensity modulated radiation therapy].

Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2013 Nov;27(21):1177-83

Objective: To retrospectively analyze the long-term curative effects and prognostic factors of 137 cases of NPC patients treated with intensity modulated radiation therapy.

Method: The three-dimensional conformal intensity modulated radiation therapy adopted for the design plan of 137 cases of newly diagnosed and no distant metastatic NPC patients. Evaluation of short-term clinical efficacy was made according to the efficacy evaluation criteria of WHO solid tumor one month after radiotherapy. During the 2 years after radiotherapy, re-examinations were made every 3 months. Two years later, re-examinations were made every 6 to 12 months, and the routine examinations included clinical body check, nasopharyngoscope, CT, B Chao, MRI, chest X-ray, bone scan, so as to understand the condition of cavum nasopharyngeum, cervical lymph nodes and cranial nerves. Life table method was adopted to calculate the overall survival rate, Kaplan-Meier method was used to calculate relapse-free survival rate, distant metasis-free survival rate and disease-free survival rate. Log-rank test was used for univariate analysis of 14 clinical factors which may exert influences on prognosis. Multivariate analysis was performed with the Cox regression model, P < 0.05 is of statistical significance.

Result: (1) Of the 137 cases, the overall survival rates of 1-year, 3-year and 5-year were 98.5%, 90.3%, 74.6% respectively, relapse-free survival rates were 97.0%, 81.9%, 66.7% respectively; distant metasis-free survival rates were 96.3%, 80.5%, 56.0% respectively; disease free survival rates were 95.6%, 76.9%, 43.8% respectively. (2) Univariate analysis revealed that the influences of T-staging,N-staging, 92 Fuzhou clinical staging, combined chemotherapy, skull base bone destruction, injury of cranial nerve, retropharyngeal lymph node metastasis, residual disease, total time of IMRT on prognosis were of no statistical significance(with all the P values lower than 0.05) The influences of gender, nationality, age, pathological type and anemia or on prognosis were of no statistical significance(with all the P values higher than 0.05). (3) T-staging, skull base bone destruction, injury of cranial nerve, retropharyngeal lymph node metastasis, N-staging, combined chemotherapy, residual disease, total time of IMRT, and anemia were drawn into Cox model, and the results showed that N-staging, combined chemotherapy, injury of cranial nerve, residual disease, and total time of IMRT were independent factors that affect prognosis (with all P values lower than 0.05).

Conclusion: IMRT obviously has advantages than conventional radiotheraphy in treating NPC patients. N-staging, injury of cranial nerve, combined chemotherapy, residual disease, and total time of IMRT are the main factors that affect prognosis.
View Article and Find Full Text PDF

Download full-text PDF

Source
November 2013

[Effect of two short striae incision or traditional "L" shaped incision in neck dissection of differentiated thyroid carcinoma on serum trauma cytokines].

Zhong Nan Da Xue Xue Bao Yi Xue Ban 2012 Dec;37(12):1260-4

Department of Mammary Gland, Tumor Hospital of Xinjiang Medical University, Urumqi, China.

Objective: To compare the trauma of neck dissection on the human body between two-striae incision and traditional "L" shaped incision by serum trauma cytokines.

Methods: Patients with differentiated thyroid carcinoma hospitized from December 2008 to July 2011 were divided into 2 groups according to their own will. The first group 26 patients) had two-striae incision and the second group 32 patients) had traditional "L" shaped incision. The serum level of interleukin(IL)-2, IL-6 and C-reactive protein (CRP) in all patients were examined 1 day before and 1, 3 and 5 days after the surgery.

Results: No statistical significance was found between the 2 groups, although level of IL-2 decreased 1 day after the surgery, but recovered to normal 3 days later. The level of IL-6 in both groups increased 1 day after the surgery, began to decrease 3 days after the surgery, and recovered to normal 5 days after the surgery. The level of CRP suggested statistical significance (P<0.05), which increased obviously 1, 3 and 5 days after the surgery. No statistical difference was found before or after the surgery between the 2 groups (P>0.05). After follow-up for 8-40 months, no local recurrence or lymph node metastasis was found.

Conclusion: Compared with the traditional "L" shaped incision, two-striae incision in neck dissection does not increase the serum level of trauma cytokines and trauma to human body after the surgery. Two-striae incision is an ideal surgical approach to differentiated thyroid carcinoma.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.3969/j.issn.1672-7347.2012.12.014DOI Listing
December 2012

[Effectiveness of pedicled sternocleidomastoid muscle flap in repairing defect after parotidectomy].

Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 2012 Mar;26(3):313-5

Department of Mammary Gland, Head and Neck Surgery, Affiliated Tumor Hospital, Xinjiang Medical University, Urumqi Xinjiang 830011, PR China.

Objective: To investigate the effectiveness of pedicled sternocleidomastoid muscle flap in repairing defect after parotidectomy by comparing with direct suture.

Methods: The clinical data were retrospectively analyzed, which were from 73 patients with parotid tumor undergoing parotidectomy between January 2002 and April 2010. After parotidectomy, defects were repaired with pedicled sternocleidomastoid muscle flap in 38 cases (flap group) and with direct suture in 35 cases (control group). There was no significant difference in gender, age, disease duration, tumor location and size between 2 groups (P > 0.05). Meanwhile the complications, such as local intercession deformity, Frey's syndrome and parotid gland fistula were observed.

Results: In flap group, the flaps were all alive and incisions healed by first intention; in control group, all incisions healed by first intention. All patients were followed up 6-98 months and no tumor recurred. There was significant difference in local intercession deformity between 2 groups (chi2 = 53.202, P = 0.000). The parotid gland fistula was found in 1 case (2.6%) of the flap group and in 8 cases (22.8%) of the control group, Frey's syndrome was found 1 case (2.6%) of the flap group and in 20 cases (57.1%) of the control group, showing significant differences between 2 groups (P < 0.05).

Conclusion: The use of pedicled sternocleidomastoid muscle flap for defect repair after parotidectomy can avoid the complications of local intercession deformity, Frey's syndrome, and parotid gland fistula.
View Article and Find Full Text PDF

Download full-text PDF

Source
March 2012

[Hashimoto's disease complicated with thyroid cancer: 54 cases].

Zhong Nan Da Xue Xue Bao Yi Xue Ban 2011 Aug;36(8):765-7

Department of Oncosurgery, Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi 830011, China.

Objective: To investigate the clinical characteristics and surgical treatment of Hashimoto's disease complicated with thyroid cancer.

Methods: Clinical data of 54 patients with Hashimoto's disease complicated with thyroid cancer were retrospectively analyzed, including clinical characteristics, surgical treatment, and short-term effects.

Results: The rate of Hashimoto's disease complicated with thyroid cancer was 14.9%, 54 out of in 362 patients with Hashimoto's disease. All the 54 patients had surgical treatment in proper thyroid region, took euthyrox after the operation and had 6 month to 4 year followup. One patient had a local recurrence and 3 had lymph node metastasis in the neck, and these 4 patients had second operation on the thyroid gland. No death occurred.

Conclusion: Hashimoto's disease complicated with thyroid cancer has no typical symptoms.Combined examination of anti-thyroid antibodies test, color doppler imaging, CT detection, isotope scan and core/fine needle biopsy may provide accurate diagnosis. Proper surgical treatment is effective for Hashimoto's disease complicated with thyroid cancer.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.3969/j.issn.1672-7347.2011.08.012DOI Listing
August 2011
-->